Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2.

Freddy T NguyenTayler van den AkkerKimberly LallyHansen LamVolha LenskayaSean T H LiuNicole M BouvierJudith A AbergDenise RodriguezFlorian KrammerDonna StraussBeth H ShazLouella RudonPatricia GaldonJeffrey S JhangSuzanne A Arinsburg Ian Bainenull null

Published in: Transfusion (2020)

Our findings support the use of CP as a safe, therapeutic option from a transfusion reaction perspective, in the setting of COVID-19. Further studies are needed to confirm the clinical significance of ABO group B, age, and predisposing disease severity in the incidence of transfusion reaction events.

Keyphrases

sars cov
cardiac surgery
coronavirus disease
respiratory syndrome coronavirus
sickle cell disease
acute kidney injury
risk factors
case control
electron transfer